BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2035 related articles for article (PubMed ID: 20557366)

  • 21. One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection.
    Lara LF; Cisneros G; Gurney M; Van Ness M; Jarjoura D; Moauro B; Polen A; Rutecki G; Whittier F
    Arch Intern Med; 2003 Sep; 163(17):2079-84. PubMed ID: 14504122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial.
    Francavilla R; Lionetti E; Castellaneta SP; Magistà AM; Boscarelli G; Piscitelli D; Amoruso A; Di Leo A; Miniello VL; Francavilla A; Cavallo L; Ierardi E
    Gastroenterology; 2005 Nov; 129(5):1414-9. PubMed ID: 16285942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic].
    Gisbert JP; Boixeda D; Martín de Argila C; Redondo C; Moreno L; Abraira V; García Plaza A
    Med Clin (Barc); 1998 Jan; 110(1):1-5. PubMed ID: 9527978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
    Malfertheiner P; Bazzoli F; Delchier JC; Celiñski K; Giguère M; Rivière M; Mégraud F;
    Lancet; 2011 Mar; 377(9769):905-13. PubMed ID: 21345487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea.
    Kim YS; Kim SJ; Yoon JH; Suk KT; Kim JB; Kim DJ; Kim DY; Min HJ; Park SH; Shin WG; Kim KH; Kim HY; Baik GH
    Aliment Pharmacol Ther; 2011 Nov; 34(9):1098-105. PubMed ID: 21923713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
    Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant effect of vitamin C on omeprazole-amoxicillin-clarithromycin triple therapy for Helicobacter pylori eradication.
    Chuang CH; Sheu BS; Kao AW; Cheng HC; Huang AH; Yang HB; Wu JJ
    Hepatogastroenterology; 2007; 54(73):320-4. PubMed ID: 17419283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Helicobacter pylori eradication with ecabet sodium, omeprazole, amoxicillin, and clarithromycin versus bismuth, omeprazole, amoxicillin, and clarithromycin quadruple therapy: a randomized, open-label, phase IV trial.
    Liang J; Li J; Han Y; Xia J; Yang Y; Li W; Zhang S; Wu Y; Yuan Y; Li Z; Du Y; Chen M; Chen B; Jiang B; Bai Y; Wen Q; Wu K; Fan D
    Helicobacter; 2012 Dec; 17(6):458-65. PubMed ID: 23066868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
    Magaret N; Burm M; Faigel D; Kelly C; Peterson W; Fennerty MB
    Dig Dis; 2001; 19(2):174-8. PubMed ID: 11549829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children.
    Bontems P; Kalach N; Oderda G; Salame A; Muyshont L; Miendje DY; Raymond J; Cadranel S; Scaillon M
    J Pediatr Gastroenterol Nutr; 2011 Dec; 53(6):646-50. PubMed ID: 21701406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.
    Oh HS; Lee DH; Seo JY; Cho YR; Kim N; Jeoung SH; Kim JW; Hwang JH; Park YS; Lee SH; Shin CM; Cho HJ; Jung HC; Song IS
    J Gastroenterol Hepatol; 2012 Mar; 27(3):504-9. PubMed ID: 21916989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori.
    Gisbert JP; Calvet X
    Aliment Pharmacol Ther; 2011 Sep; 34(6):604-17. PubMed ID: 21745241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
    Chuah SK; Tai WC; Hsu PI; Wu DC; Wu KL; Kuo CM; Chiu YC; Hu ML; Chou YP; Kuo YH; Liang CM; Chiu KW; Hu TH
    Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial.
    Cuadrado-Lavín A; Salcines-Caviedes JR; Carrascosa MF; Dierssen-Sotos T; Cobo M; Campos MR; Ayestarán B; Fernández-Pousa A; González-Colominas E; Aresti-Zárate S; Hernández M; Pascual EL
    J Antimicrob Chemother; 2012 Sep; 67(9):2254-9. PubMed ID: 22687889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial.
    Romano M; Cuomo A; Gravina AG; Miranda A; Iovene MR; Tiso A; Sica M; Rocco A; Salerno R; Marmo R; Federico A; Nardone G
    Gut; 2010 Nov; 59(11):1465-70. PubMed ID: 20947881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori.
    Uygun A; Kadayifçi A; Yeşilova Z; Savaş MC; Ateş Y; Karslioğlu Y; Ciğerim M; Bağci S; Dağalp K
    Turk J Gastroenterol; 2004 Dec; 15(4):219-24. PubMed ID: 16249974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance.
    Zheng Q; Chen WJ; Lu H; Sun QJ; Xiao SD
    J Dig Dis; 2010 Oct; 11(5):313-8. PubMed ID: 20883428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.
    Molina-Infante J; Perez-Gallardo B; Fernandez-Bermejo M; Hernandez-Alonso M; Vinagre G; Dueñas C; Mateos-Rodriguez JM; Gonzalez-Garcia G; Abadia EG; Gisbert JP
    Aliment Pharmacol Ther; 2010 May; 31(10):1077-84. PubMed ID: 20180787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
    Zhang W; Chen Q; Liang X; Liu W; Xiao S; Graham DY; Lu H
    Gut; 2015 Nov; 64(11):1715-20. PubMed ID: 26338726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 102.